Collectively, these results suggest that neutrophil activation during tumor progression is constrained by ACKR2, which impinges on their expression of CC chemokine receptors and inhibits their migration to the lung and their ability to generate ROS, key mediators of neutrophil antitumoral potential29,30. This evidence concerns the gene ACKR2 and neoplasm.